Demant AS
DEMANT: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 816.00 | Nnvxly | Zwshmnmt |
Demant: Implants Divestiture to Cochlear Provisionally Challenged but We Anticipate It Will Proceed
Narrow-moat Demant announced that the UK Competition and Markets Authority's provisional finding (prior to the final report in early June) is that the divestment of Oticon Medical to Cochlear Ltd. could create a "substantial lessening of competition" in the region. The implants divestiture was expected to close in the second quarter of 2023, but it is now doubtful given the CMA's preliminary findings. Demant and Cochlear are also awaiting decisions from various other entities regarding the effects on competition and foreign direct investments.